ISRCTN84512041进行中（未招募）1 期
A single-center, open-label, two-period study to investigate the effect of multiple-dose itraconazole, a strong CYP3A inhibitor, on the pharmacokinetics of a single dose of RO7269162 in healthy participants
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Body mass index (BMI) of 18 to 30 kilograms per metre squared (kg/m2) inclusive (at screening)
- •2. Participants who are overtly healthy determined by no clinically significant findings from medical history, 12-lead electrocardiogram (ECG), or vital signs
排除标准
- •1. History or presence of any clinically significant cardiovascular, bronchopulmonary, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, psychiatric, genitourinary, metabolic disorders, allergic diseases, cancer, or cirrhosis
- •2. History or evidence of any medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs
- •3. Surgical history of the gastrointestinal tract affecting gastric motility or altering the gastrointestinal tract
- •4. History of malignancy in the past 5 years
- •5. Known active or uncontrolled bacterial, viral, fungal, mycobacterial infection, or other Infection
- •6. Participation in an investigational drug study involving any therapeutic monoclonal antibody
- •7. Positive test for drugs of abuse or alcohol
- •8. Positive result on human immunodeficiency virus (HIV) 1 and HIV2, hepatitis C virus (HCV) or hepatitis B virus (HBV)
- •9. Participants who have donated over 500 milliliters (mL) of blood or blood products or had significant blood loss within 3 months before screening.
研究者
相似试验
尚未招募
不适用
A single-center, prospective, open-label study investigating the effect of Ninjin'yoeito on frailty in hemodialysis patients.frailty in hemodialysis patientsJPRN-UMIN000052058Japanese Red Cross Kumamoto Hospital40
进行中（未招募）
不适用
An open-label, one-period, one-treatment study which objective is to evaluate the time course of the antiproteinuric and blood pressure lowering effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathyHypertensionEUCTR2005-000361-19-DKovartis Pharma Services AG18
已完成
Unknown
A Clinical Study to check the safety and effectiveness of AVL200 Modular Intraocular Lens.CTRI/2023/05/052664ATIA VISION,INC100
进行中（未招募）
1 期
A Study of Nasal Glucagon in Children with Insulin Dependent Diabetessevere hypoglycemiaEUCTR2021-006088-61-Outside-EU/EEAEli Lilly and Company
进行中（未招募）
1 期
Study to investigate the effect of riociguat on right heart size and function in pulmonary hypertensioSymptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance =2 Wood Units, pulmonary arterial wedge pressure =15 mmHg (Group I / Nice Clinical Classification of Pulmonary Hypertension (PH)) or CTEPH (Group IV) with hemodynamics as stated above defined as inoperable measured at least 3 months after start of full anticoagulation or with persisting or recurrent PH after pulmonary endarterectomy at least 6 months after surgeryMedDRA version: 20.0Level: HLTClassification code 10037401Term: Pulmonary hypertensionsSystem Organ Class: 100000004855EUCTR2020-005462-34-DEThoraxklinik Heidelberg gGmbH30